Beyond AWP … Way Beyond  by Willke, Richard J.
Beyond AWP . . . Way Beyondvhe_673 1
Richard J. Willke, PhD
Pﬁzer, Inc., Global Health & Outcomes Research, Primary Care, Peapack, NJ, USA
Keywords: AWP, CEA, drug cost standards, scientiﬁc report.
First of all, congratulations and kudos to the ISPOR Drug Cost
Standards Task Force, led by Joel Hay and Jim Smeeding. Their
combined report represents several years of hard work and rec-
ognition that there were a number of important aspects to the
question of drug costing that merited full exploration and expli-
cation. Producing this well-coordinated series of reports is a real
accomplishment and a major contribution to our ﬁeld.
Many people think that costing drugs is mainly about
getting the accounting details right. Though several of these
reports do pay close attention to such detail, the overview and
the societal perspective articles focus more heavily on the eco-
nomic costs, that is, the opportunity costs, of producing drugs.
It provides an important, fascinating, and underdiscussed set of
considerations around what the real costs of drugs are. Getting
this right can be very important in CEA. As we all know, the
intervention drug cost is usually the main driver of the “DC” in
the ICER’s numerator.
A key consideration in the societal perspective report is that
new drugs are generally priced at monopolistically determined
levels due to patent protection rather than at marginal-cost-of-
production levels. The short-term resource cost of production is
thus well below the market price, and, depending on the nature
of the decision to be made, it may only be the marginal resource
cost that is relevant to the societal perspective. The remainder of
the drug price really goes toward “producer surplus” or alterna-
tively can be considered a return on past R&D costs or simply
as “transfer” to the producer, but in none of these views is it a
short-term resource cost. So, are the societal costs of new drugs
really overstated in most analyses, leading to ICER’s that are too
high? Should pharma be asking all the societal decision-makers
for recounts on drugs they have recently turned down? It’s not
quite that simple, of course, but reading the reports is worth the
trip on this question. You will read about a “limited societal”
perspective and more.
There are a couple of issues embedded here that are worthy of
comment. First, as you would expect, the societal perspective
report discusses the need to consider R&D costs as part of
societal costs in the long term as an aspect of dynamic efﬁciency.
Somewhat overlooked is the role of expectations of producers,
who are increasingly making R&D investment decisions based
on the likelihood that the drug will pass muster as being cost-
effective. Raising or lowering those hurdles will affect R&D
decisions and must be considered in discussions of dynamic
efﬁciency.
Though really a sidebar to the overall report, the notion of
patent buyouts is an interesting thought exercise. The idea here is
that there may be mechanisms by which the government could
“buy out” a drug patent, say, shortly after FDA approval, reward
the producer for the innovation in a market-determined way, and
then allow the drug to be produced and sold by all comers, as if
generic, thus reducing the market price to marginal cost levels
and enabling more widespread and potentially socially optimal
use much earlier than usual. There are a number of consider-
ations here, and I recommend reading Michael Kremer’s article
(referenced in the societal report) for those who are interested in
thinking more about how this might work. Personally, I am most
dubious about the feasibility of funding such buyouts in political
economy sense. Some buyouts would involve multibillion dollar
payments to drug makers for the “expected future value” of a
drug. Will that be acceptable politically? More importantly,
which governments are going to pitch in for these buyouts? All
countries would beneﬁt from them, but what is each one’s fair
share? The potential for free ridership here seems enormous, even
worse than under our current system.
The subsequent reports take different perspectives: those of
the managed care payer, the US government payer, the industry,
and several countries, representing the international perspective.
All of them are well done and make important points. If you
cannot read them all in one sitting, take them along as plane/
train/bus reading. The following comments are offered simply as
potential points of reﬂection as you read them.
The managed care payer report is excellent. Interestingly, it
includes the recommendation that the drug cost used in budget
impact and CEA models net out patient copays. This clearly
makes sense for budget-impact models. But what does it mean
for CEA results? That the higher the patient copay, the more
cost-effective a drug will be? It implies that an MCO can provide
highly cost-effective care by making a patient pay the whole drug
cost. Try pitching that one to an employee beneﬁts group.
The report by the US Government Payers Subgroup is a tour
de force of public program regulations around pricing, and I
would highly recommend it for anyone who needs to bone up on
the how Medicare, Medicaid, VA, and other program pricing
regulations have evolved recently. Just one caveat: government
being what it is, the report is acronym rich; I stopped counting at
25.
The industry report provides a needed emphasis on value
versus cost comparisons, transparency, and credibility in evalu-
ation of drug therapy. The international report not only shares a
helpful sampling of how drug prices are determined in some
representative countries but also reviews some controversies in
international economic evaluations.
Taken all together, one comes away with two impressions.
First, drug costing is indeed “complicated,” as noted in the
overview report. Second, it seems abundantly clear—as if it
wasn’t already—that CEA results are likely to vary signiﬁcantly
from one perspective to another, based on drug costing alone.
Although having a centrally carried out CEA by a national
authority may seem efﬁcient in some ways, the potential for its
results to be inapplicable to many local situations seems very
high.
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